A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01731301|
Recruitment Status : Unknown
Verified November 2012 by Liver Institute of Virginia.
Recruitment status was: Not yet recruiting
First Posted : November 21, 2012
Last Update Posted : November 22, 2012
- A maximally tolerated dose of ribavirin can be defined in each patient with ESRD undergoing hemodialysis.
- Patients with Chronic Hepatitis C Virus (HCV)and End-Stage Renal Disease (ESRD)undergoing hemodialysis will be able to tolerate and remain on treatment with peginterferon alfa-2b, the maximally tolerated dose of ribavirin and boceprevir.
- A significant percentage of patients with chronic HCV and ESRD undergoing hemodialysis can achieve rapid virologic response (RVR), extended virologic response (eRVR) and sustained virologic response (SVR) when treated with peginterferon alfa-2b, the maximally tolerated dose of ribavirin and boceprevir.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Hepatitis C End Stage Renal Disease||Drug: Ribavirin Drug: Peginterferon Drug: Boceprevir||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir|
|Study Start Date :||January 2013|
|Estimated Primary Completion Date :||January 2014|
|Estimated Study Completion Date :||January 2015|
Experimental: Ribavirin, peginterferon, boceprevir
The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir.
Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
Other Name: Rebetol
After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
Other Name: PegIntron, Rebetol and Victrelis
Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
Other Name: Victralis
- Percentage of patients who achieve eRVR at treatment week 28 [ Time Frame: 28 weeks ]The primary end-point for evaluation will be the percentage of patients who achieve eRVR at treatment week 28.
- Tolerability of treatment [ Time Frame: 48 weeks ]A. The ability to define the maximal tolerated dose of ribavirin. B. The ability to remain on peg-interferon alfa-2b, ribavirin and boceprevir for 24 weeks C. The percentage of patients who achieve SVR
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01731301
|Contact: Mitchell L Shiffman, MDfirstname.lastname@example.org|
|Contact: April G. Long, NPemail@example.com|
|United States, Virginia|
|Liver Institute of Virginia||Not yet recruiting|
|Richmond, Virginia, United States, 23226|
|Contact: Mitchell L Shiffman, MD 804-977-8920 firstname.lastname@example.org|
|Principal Investigator: Mitchell L Shiffman, MD|
|Principal Investigator:||Mitchell L Shiffman, MD||Liver Institute of Virginia, Bon Secours Health System|